There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytoDyn Inc (CYDY) and Dicerna Pharma (DRNA) with bullish sentiments.
CytoDyn Inc (CYDY)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc today and set a price target of $1.50. The company’s shares closed yesterday at $0.49.
Selvaraju observed:
“Our 12-month price target is derived from an estimated market value of the firm at $560M. It includes a discounted cash flow-based asset value of $566M for leronlimab in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $6M debt.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.0% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytoDyn Inc with a $1.50 average price target.
See today’s analyst top recommended stocks >>
Dicerna Pharma (DRNA)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma today and set a price target of $22. The company’s shares closed yesterday at $11.74.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.3% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.33, implying an 81.7% upside from current levels. In a report issued on February 25, Cowen & Co. also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
